+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Opportunities for novel therapeutic agents acting at chemokine receptors



Opportunities for novel therapeutic agents acting at chemokine receptors



Drug Discovery Today 4(2): 80-92



Chemokines are proinflammatory mediators that primarily control leukocyte migration into selected tissues and upregulation of adhesion receptors. They also have a role in pathological conditions that require neovascularization and are implicated in the suppression of viral replication. By interaction with their respective G-protein-coupled receptor, chemokines have a profound influence over the selective recruitment of specific cell types in acute inflammatory disease and, hence, inhibition of their action should be of therapeutic benefit. Only now are small molecule inhibitors becoming available to validate this speculation. In this review, without seeking to be comprehensive, the authors provide an introduction to chemokines, their receptors and their role in certain disease processes. Also, recent disclosures claiming novel nonpeptide ligands for chemokine receptors are summarized.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046870075

Download citation: RISBibTeXText

PMID: 10234160

DOI: 10.1016/s1359-6446(98)01280-x


Related references

CC chemokine receptors and chronic inflammation--therapeutic opportunities and pharmacological challenges. Pharmacological Reviews 65(1): 47-89, 2013

Chemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte trafficking. American Journal of Physiology. Lung Cellular and Molecular Physiology 308(7): L603-L618, 2015

Therapeutic use of agents acting on alpha and beta receptors. Fortschritte der Medizin 92(11): 461-466, 1974

The therapeutic potential of agents acting via purine receptors. Expert Opinion on Investigational Drugs 7(2): 225-243, 1998

Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Current Topics in Medicinal Chemistry 6(13): 1345-1352, 2006

Attempted therapeutic application of agents acting on alpha and beta adrenerging receptors in experimental cardiac shock. Polish Medical Journal 8(2): 418-425, 1969

Therapeutic attempts at application of agents acting on alpha and beta receptors of the adrenergic system in experimental cardiac shock. Polskie Archiwum Medycyny Wewnetrznej 40(3): 303-309, 1968

Modulation of monoamine receptors by adaptor proteins and lipid rafts: role in some effects of centrally acting drugs and therapeutic agents. Annual Review of Pharmacology and Toxicology 51: 211-242, 2011

A CCL chemokine-derived peptide (CDIP-2) exerts anti-inflammatory activity via CCR1, CCR2 and CCR3 chemokine receptors: Implications as a potential therapeutic treatment of asthma. International Immunopharmacology 20(1): 1-11, 2014

Chemokine receptors: emerging opportunities for new anti-HIV therapies. Expert Opinion on Therapeutic Targets 5(3): 303-326, 2001

Biased agonism at chemokine receptors: obstacles or opportunities for drug discovery?. Journal of Leukocyte Biology 99(6): 901-909, 2016

Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Archives of Neurology 58(12): 1975-1980, 2001

Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine and Growth Factor Reviews 16(6): 625-636, 2005

Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. Embo Journal 23(1): 66-76, 2003

ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacology and Therapeutics 112(1): 139-149, 2006